I think this is going to get Messy and Violent.
I think this is going to get Messy and Violent.
And CRISPR plays a big part in Pharming!
Isn’t this phun?
From future-science.com written in 2018
Recently I wrote an article in which “Vaccines in your Salad” was brought to light. I had an unusual number of people emailing me that I had gone off the rails.
Perhaps after reading this article, those nay- sayers will be whistling a different tune.
For the past week, I have been wondering about and researching reasons why Bill Gates has become the number one Farmland owner in the whole U.S.
One thing was certain to me: it must have to do with VACCINES.
Most of us know that VACCINES are near and dear to the heart (does he have one?) of Pharmer Bill:
Plants in the CRISPR
From gene-edited human embryos to disease-free pigs for donor organs, applications of CRISPR/Cas9 technology are filling the headlines. But the impact of this gene-editing technique isn’t limited to biomedical research: Plant biologists are also using CRISPR to study molecular mechanisms underlying plant function, fight disease, and enhance plant productivity.
“The CRISPR craze has pretty much swept through plant biology,” says Dan Voytas of the University of Minnesota. “I would say most groups doing plant gene editing are using CRISPR or similar reagents.” As a result, CRISPR/Cas9 could prove pivotal in addressing the challenge of feeding the world’s growing population, which is expected to approach 10 billion by 2050.
Transgenic plants (also know as genetically modified organisms or GMOs) have been around for decades. But the insertion of foreign genes and DNA to produce desirable traits has prompted controversy as well as rejection of these plants by some consumers. In recent years, biologists have been developing more tailored methods for altering genomes that complement traditional plant breeding strategies and dovetail with new genetic tools. Until the advent of CRISPR within the past 5 years, one of the more promising gene-editing technologies was TAL effector nucleases (TALENs), which were developed from building blocks that occur naturally in plants.
However, CRISPR/Cas9 has largely overtaken other gene-editing techniques. Researchers tell similar stories: A few years ago, they started working on projects using both TALENs and CRISPR/Cas9 side-by-side, but quickly settled on CRISPR. While both techniques offer precise editing, TALENs are large, complex proteins that must be newly synthesized for each mutation, says Becky Bart of the Donald Danforth Plant Science Center in St. Louis. But using CRISPR/Cas9, a researcher needs only to develop new guide RNAs, she says, and “very quickly you can test a bunch of constructs right in the lab.” As a result, CRISPR is both cheaper and faster, says Bing Yang of Iowa State University. And combining CRISPR with a traditional plant breeding program offers the most potential for making precise changes quickly.
That doesn’t mean TALENs and other methods are completely out of the picture though. With the continuing uncertainty surrounding the patents and licensing of CRISPR technology, many companies are still centering their work around technologies such as TALENS and meganucleases, where the intellectual property rights are clear, says Voytas, who was one of the early developers of TALENs and is the Chief Science Officer of Calyxt—a Minnesota-based plant gene-editing company focusing on that technology (see “Legal and regulatory hurdles” sidebar).
Scientists have long mined natural plant mutants that show up in fields or used random mutagenesis as a tool for understanding gene function in crops. “Hopefully, you hit a gene; hopefully, you get a change in the phenotype of interest, the trait of interest, and then you try to pin down which gene is broken,” says Zach Lippman of Cold Spring Harbor Laboratory in New York. His laboratory focuses on understand the flowering process, particularly in tomatoes and the related Solanaceae (nightshade) family, so that they can ultimately manipulate the process to improve agriculture.
Brothers and sisters in Christ, this is a rather long article, and for those who wish to read it in its entirety, they can click HERE
But for the purpose of posting this piece, I will go right to the last few paragraphs. There you will see how the author plopped in the word we were all waiting for:
Despite the technical hurdles, CRISPR/Cas9 is changing plant biology as fast as it is revolutionizing other fields. Just a few years ago, a research article might have highlighted the ability to mutate plant genes using CRISPR, but now the title touts a better understanding of plant architecture, with CRISPR embedded in the Materials and Methods section. “I’m not saying that we don’t have a lot of work yet to do on technology development,” Voytas says, but he adds that it’s satisfying to see this shift. “It’s become the tool and not the story.”
With the investments made by researchers and industry, Kamoun sees CRISPR-based gene-editing technology as maturing relatively rapidly in plants. “I think the challenge now becomes about finding the traits,” he says. For a long time, plant biologists didn’t have the tools to apply the knowledge that they’d gained about interesting plants genes and then deliver those results to farmers. But now they have the technology, he says. “We need more research to actually understand what all of the genes are doing in plants and how we can tweak them and improve them.”
After years of mostly reading genomes, researchers are editing and moving toward rewriting those genomes in increasingly sophisticated ways, Voytas says. Synthetic biology, though rudimentary right now, could help modify plant genes to produce rare metabolites or even PHARMACEUTICALS of interest. Such technologies could allow researchers to modify nutrient content to lower gluten levels in bread or optimize the fatty acid content in cooking oil. “The possibilities are limitless, but the editing allows us to start to harness and control those metabolic pathways,” he concludes. (emphasis added)source
So now when you read about the “plant-based proteins” which Gates has in store for us to consume – PLEASE remember this article!!
Do you remember during the Obama Regime when BHO closed the door on Bibi as he said he was going to eat dinner? The LEFT = SATANIC
BIDEN’S HOSTILE VISIT TO THE MIDDLE EAST
Former Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb said Sunday on CBS’s “Face the Nation” that the window to control the spread of the monkeypox virus in the United States may be closed.
Partial transcript as follows:
MARGARET: Give us a sense of the scale of this because the CDC numbers are out. They say they’re only eight women within that. No children. You’re saying this is a pandemic? That’s not a word the administration is using yet, what level of emergency are we at?
GOTTLIEB: Yeah look, and I think they’re going to be reluctant to use the word pandemic, because it implies that they’ve failed to contain this. And I think at this point, we’ve failed to contain this. We’re now at the cusp of this becoming an endemic virus where this now becomes something that’s persistent that we need to continue to deal with. I think the window for getting control of this and containing it probably has closed, and if it hasn’t closed, it’s certainly starting to close. 11,000 cases across the world right now. 1,800 cases, as you said, in the US. We’re probably detecting just a fraction of the actual cases because we have a very, we had for a long time a very narrow case definition on who got tested. And by and large, we’re looking in the community of men who have sex with men and STD clinics. So we’re looking there, we’re finding cases there. But it’s a fact that there’s cases outside that community right now. We’re not picking them up, because we’re not looking there. This has spread more broadly in the community. I wouldn’t be surprised there’s thousands of cases right now.
BRENNAN: It’s a little chilling to hear you say containment has failed. I’ve heard you say that before with COVID.
GOTTLIEB: Well look, this isn’t going to explode like COVID. This is a slower moving virus, which is why we could have gotten control of this if we had been more aggressive up front, and we made a lot of the same mistakes that we made with COVID with this – having a very narrow case definition not having enough testing early enough, not deploying vaccine in an aggressive fact- fashion to ring vaccinate. But now this is firmly embedded in the community. And while it’s not going to explode, because it’s harder for this virus to spread, it’s probably going to be persistent, you’ll-you’ll have this as a sort of a fact of life, maybe spreading as a sexually transmitted disease, but also breaking out of those settings.
BRENNAN: So the CDC said monkey pox can show up up to three weeks post exposure. What are the basic symptoms? If you have a rash you call your dermatologist? Who do you call?
GOTTLIEB: Well, it’s a vesicular rash. It’s associated with fever and achiness. You know, the historically used to get a disseminated rash. What we’re seeing right now is people aren’t presenting with a widely diffused rash, but sometimes just a small number of vesicles. So I think it’s being confused with other vesicular rashes, Herpes, Coxsackie could cause a vesicular rash, certainly chickenpox. Right now, anyone who presents with a particular rash that can’t be explained by another etiology. So a rash that causes vesicles, should be tested for monkey pox, whether they come from a high risk community or not. That’s the way we’re going to snuff this out. We didn’t have enough testing to do that. Now CDC has gotten in place more testing this probably adequate testing to broaden it to-to accomplish that. So we should be doing that physicians should be sending off these tests.
BRENNAN: The problem with testing also, it seems that distribution or access to a vaccine is an issue, the mayor of New York, the governor of New York, asking the Biden administration to do more to get them access. Why is this a problem?
GOTTLIEB: Well, we didn’t have adequate stockpiles of the vaccine, the one vaccine that’s proven monkeypox, we only had 2,000 doses in a national strategic stockpile. It was there as a hedge against smallpox, we took our eye off that ball, so we didn’t replenish that supply. They ordered about 300,000 doses that have been delivered. 150,000 have been distributed, another 130,000 will go out this week.
BRENNAN: Some of that overseas.
GOTTLIEB: Some of it- well, there’s 800,000 doses that were overseas, that the manufacturer, Bavarian Nordic, had overseas. Those are being brought into the US right now. FDA has to do what’s called “lot release”, they have to inspect those doses to make sure they were appropriately manufactured. They’re doing that inspection at the same time that they’re forward deploying those 800,000 doses. So those are going to cities right now. And as soon as FDA finishes that, which should be this week, those doses will be turned on, they’ll be able to be distributed or be used on patients. So I think the vaccine situation is going to improve dramatically this week, you’re going to see literally hundreds of thousands of doses become available. The White House has intervened to take more control of the response away from CDC. This can’t be our response every time that when CDC drops the ball, the White House and the political leadership need to step in. That’s what’s happened here. It happened in COVID. We need to fundamentally reform how we respond to these-these crises.
BRENNAN: You wrote a book on that. I want to ask you about COVID. The CDC says now about 54% of Americans live in an area of high COVID Community spread. That’s up from 31%, the prior week, that seems fast moving. What is different about these variants now?
GOTTLIEB: Well, look, it’s the B-5 variant that’s growing. It has the capacity to evade the immunity that we’ve acquired from vaccination and also from prior infection. It does seem to be that B-2 infection confers more robust immunity against this B-5 variants, so places that had big outbreaks of B-2, like the Northeast, are probably going to be more protected. There’s 100,000, over 100,000 cases on average being reported on a daily basis. We’re probably detecting one in 10 infections right now. So it’s probably more like a million. I think most Americans have started to accept this as part of the fabric of daily living. In part that’s, that’s based on a wholesale recalibration of risk, in part is based on the fact that there’s very few people who are immune. I.e so people feel rightly, more impervious to a bad outcome. So we have to recognize that this spread is happening against the backdrop basically, of normal living.
BRENNAN: But the White House is saying put a mask on if you go into indoor gatherings, the city of Los Angeles says they might institute this at the end of the month.
GOTTLIEB: I don’t think we’re going to see mandates. I don’t think there’s a lot of tolerance for mandates, maybe in select cities, like Los Angeles.
BRENNAN: But is it advisable?
GOTTLIEB: I think if you’re going into a congregate setting with a lot of people you don’t know, wearing a mask is prudent if you’re in a high prevalence area, especially if you’re someone who-who’s at risk. You know, I still wear a mask in certain settings, I wear when I go through the airport. If I catch COVID I want it to be from a family member or friend not some stranger I’m sitting next to on a plane. So I try to be prudent when I’m in mixed company. I think right now, if you live in a high prevalence region, it’s advisable, especially if you’re someone who’s vulnerable if it’s easy enough.
BRENNAN: And a booster shot. Will we have a rebooted bivalent vaccine in the fall?
GOTTLIEB: Yeah,well, look, there’s going to be a vaccine based on B-4 that the manufacturers are developing right now. There is a bivalent vaccine based on B-1 on the shelf right now that we could be deploying, we’re not. That probably would be more protected against this B-4 variant and B-5 variant. We- they’ve made a decision so far not to deploy that but to wait for the B-4 variant vaccine that’s going to be available this fall. Right now, if you’re above the age of 50 and you haven’t had a dose of vaccine this year, you probably should get one, and as sequencing is good, get a dose now if you’re someone who’s at high risk and come back and get one later. SOURCE
And DON’T get Jabbed!